Effect Evaluation of Clinical Pharmacists Participating in the Therapy of Benign Prostatic Hyperplasia
- VernacularTitle:临床药师参与良性前列腺增生治疗的效果评价
- Author:
Yanning JIA
1
;
Rui WANG
1
;
Yuanqing BIAN
1
;
Chunxiang ZHANG
1
Author Information
1. Dept. of Pharmacy，Nanjing Jiangning Hospital，Nanjing 211100，China
- Publication Type:Journal Article
- Keywords:
Benign prostatic hyperplasia;
Clinical pharmacist;
Pharmaceutical care;
Medication adherence;
Disease
- From:
China Pharmacy
2021;32(16):2035-2039
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To explore the effect of clinical pharmacists participating in the therapy of benign prostatic hyperplasia （BPH），and to provide reference for clinical pharmacists participating in the management of chronic diseases. METHODS：Totally 195 BPH patients ，admitted to urology outpatient department of Nanjing Jiangning Hospital during Jan. 2018 to Nov. 2019，were collected and divided into intervention group （98 cases）and control group （97 cases）according to visiting order. Patients in the control group received routine outpatient service of urology surgery . Clinical pharmacists took the initiative to provide individualized pharmaceutical care for intervention group on the basis of routine service ，which mainly included BPH disease education ，healthy lifestyle guidance ，and guidance on rational drug use. International prostate symptom score （IPSS）， quality of life score （QOL），medication adherence and disease progression were compared between 2 groups before intervention and at 2，4，6 and 9 months of follow-up. RESULTS ：Because 15 patients in intervention group lost follow-up ，83 cases were included in the intervention group and 97 cases were included in the control group. Before the intervention ，there was no statistical significance in general information ，IPSS，QOL scores and medication adherence between 2 groups（P＞0.05）. Compared with control group ，IPSS score and QOL score of intervention group were significantly decreased at 2，4，6 and 9 months of follow-up （P＜0.001）；the proportion of patients with high medication adherence in the intervention group increased significantly （P＜ 0.001）；there was no significant difference in disease progression as urinary tract infection between 2 groups （P＞0.05）. CONCLUSIONS：The participation of clinical pharmacists in the treatment of BPH can significantly decrease IPSS score and QOL score，and improve medication adherence and therapeutic effect.
